__timestamp | Bio-Techne Corporation | Sanofi |
---|---|---|
Wednesday, January 1, 2014 | 60716000 | 8565000000 |
Thursday, January 1, 2015 | 119401000 | 9496000000 |
Friday, January 1, 2016 | 140879000 | 9592000000 |
Sunday, January 1, 2017 | 199243000 | 10164000000 |
Monday, January 1, 2018 | 240636000 | 9934000000 |
Tuesday, January 1, 2019 | 264359000 | 9883000000 |
Wednesday, January 1, 2020 | 260583000 | 9390000000 |
Friday, January 1, 2021 | 324951000 | 9555000000 |
Saturday, January 1, 2022 | 372766000 | 10539000000 |
Sunday, January 1, 2023 | 378378000 | 10765000000 |
Monday, January 1, 2024 | 396826000 | 9183000000 |
In pursuit of knowledge
In the ever-evolving landscape of the pharmaceutical and biotechnology sectors, understanding the financial dynamics of industry giants is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Sanofi and Bio-Techne Corporation from 2014 to 2023. Over this period, Sanofi's SG&A expenses have consistently dwarfed those of Bio-Techne, reflecting its expansive global operations. In 2023, Sanofi's expenses peaked at approximately $10.8 billion, marking a 26% increase from 2014. In contrast, Bio-Techne's expenses grew by an impressive 554%, reaching nearly $397 million in 2024. This stark contrast highlights the differing scales and growth trajectories of these companies. Notably, the data for 2024 is incomplete for Sanofi, indicating potential shifts in financial strategies. As these companies navigate the complexities of the healthcare market, their SG&A trends offer valuable insights into their operational priorities and market positioning.
Selling, General, and Administrative Costs: Amgen Inc. vs Sanofi
Who Optimizes SG&A Costs Better? Sanofi or Takeda Pharmaceutical Company Limited
Selling, General, and Administrative Costs: Sanofi vs Biogen Inc.
Comparing SG&A Expenses: Sanofi vs Opthea Limited Trends and Insights
Who Optimizes SG&A Costs Better? Sanofi or Alpine Immune Sciences, Inc.
Selling, General, and Administrative Costs: Sanofi vs CymaBay Therapeutics, Inc.
Breaking Down SG&A Expenses: Sanofi vs Amneal Pharmaceuticals, Inc.
Sanofi and Arrowhead Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Sanofi and Xencor, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Biogen Inc. and Bio-Techne Corporation
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and Bio-Techne Corporation
SG&A Efficiency Analysis: Comparing Bio-Techne Corporation and Grifols, S.A.